| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation | $0-100.0% | $7K-55.4% | $15K-41.3% | $26K+310.9% | $6K-4.9% | $7K-71.0% | $23K+234.8% | $7K-70.5% | $23K |
| Research and development | $9.4M-10.5% | $10.5M-40.2% | $17.6M+53.1% | $11.5M+264.5% | $3.2M+7.9% | $2.9M-67.4% | $9.0M+339.7% | $2.0M-72.1% | $7.3M |
| General and administrative | $6.1M-42.7% | $10.6M-20.8% | $13.4M+9.2% | $12.3M+309.0% | $3.0M+6.0% | $2.8M-75.7% | $11.7M+257.8% | $3.3M-69.3% | $10.6M |
| Total operating expenses | $15.5M-26.7% | $21.2M-31.8% | $31.1M+30.3% | $23.8M+286.2% | $6.2M+6.9% | $5.8M-72.1% | $20.7M+289.2% | $5.3M-70.4% | $18.0M |
| Operating loss | -$15.5M+26.7% | -$21.2M+31.8% | -$31.1M-30.3% | -$23.8M-286.2% | -$6.2M-6.9% | -$5.8M+72.1% | -$20.7M-289.2% | -$5.3M+70.4% | -$18.0M |
| Other income | $27K-57.7% | $64K | — | — | — | — | — | — | — |
| Other financing costs | -$740K | $0 | — | — | — | — | — | — | — |
| Realized and unrealized loss | -$299+47.5% | -$570+96.9% | -$19K | — | — | — | — | — | — |
| Net loss | -$16.2M+23.1% | -$21.1M+31.6% | -$30.9M-30.0% | -$23.7M-286.5% | -$6.1M-6.6% | -$5.8M+72.1% | -$20.7M-289.2% | -$5.3M+70.4% | -$17.9M |
| Deemed dividend related to warrant modification | $0+100.0% | -$277K | $0 | — | — | — | — | — | — |
| Net loss attributable to common stockholders | -$16.2M+24.1% | -$21.4M+30.7% | -$30.9M | — | — | — | — | — | — |
| Net loss per share applicable to common stockholders — basic and diluted (in dollars per share) | -$17.40+93.5% | -$266.89-1083.0% | -$22.56-13.9% | -$19.80-15130.8% | -$0.13-8.3% | -$0.12+72.7% | -$0.44-300.0% | -$0.11 | — |
| Weighted average number of common shares — basic and diluted (in shares) | 933K+1063.9% | 80K-94.1% | 1.4M+14.1% | 1.2M-97.5% | 48.0M+1.8% | 47.1M | — | — | 35.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.